Browse

Clevudine therapy for 24 weeks further reduced serum hepatitis B virus DNA levels and increased ALT normalization rates without emergence of viral breakthrough than 12 weeks of clevudine therapy

Cited 12 time in Web of Science Cited 13 time in Scopus
Authors
Lee, Kwan Sik; Byun, Kwan Soo; Chung, Young-Hwa; Paik, Seung Woon; Han, Joon-Yeol; Yoo, Kwon; Yoo, Hee-Won; Yoo, Byung Chul; Lee, Hyo-Suk
Issue Date
2007-07-12
Publisher
Karger
Citation
Intervirology. 2007;50(4):296-302. Epub 2007 Jul 9.
Keywords
Alanine Transaminase/*blood*Antiviral Agents/administration & dosage/adverse effects/therapeutic useArabinofuranosyluracil/administration & dosage/adverse effects/*analogs &derivatives/therapeutic useDNA, Viral/*bloodHepatitis B e Antigens/bloodHepatitis B virus/*drug effects/genetics/isolation &purification/physiologyHepatitis B, Chronic/drug therapy/virologyHumansMaleTreatment Outcome
Abstract
OBJECTIVES: The objectives of the study were to evaluate the safety and antiviral activity of 24-week treatment with clevudine 30 mg in HBeAg(+) chronic hepatitis B patients. Biochemical and serological responses were also assessed. METHOD: Twenty-one patients received clevudine 30 mg for 24 weeks and were followed up for another 24 weeks off therapy. RESULTS: Median decreases from baseline in HBV DNA were 4.65 and 1.96 log(10) copies/ml at week 24 (end of treatment) and week 48 (24 weeks off therapy), respectively. Analysis of individual data showed that HBV DNA levels were below the lower limit of detection (300 copies/ml) by Amplicor PCR assay in 19, 57, 19 and 0% at week 12, 24, 34 and 48, respectively. The proportion of patients with normal ALT were 67, 81 and 75% at week 24 (end of treatment), 34 and 48 (24 weeks off therapy), respectively. The rates of HBeAg loss were 24 and 20% at week 24 and 48, respectively. No viral breakthrough during treatment was observed. CONCLUSION: Clevudine 30 mg treatment for 24 weeks was well tolerated and exhibited more potent antiviral activity and a higher ALT normalization rate than 12-week treatment with durable efficacy at week 24 off therapy.
ISSN
1423-0100 (Electronic)
Language
English
URI
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17622789

https://hdl.handle.net/10371/29064
DOI
https://doi.org/10.1159/000105442
Files in This Item:
There are no files associated with this item.
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Internal Medicine (내과학전공)Journal Papers (저널논문_내과학전공)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse